Given the additional link of mebendazole to ADPKD via two protein kinase targets predicted by the multiscale interactome approach, we assessed the ability of mebendazole to inhibit a diverse panel of kinases, which was enriched with additional kinase targets previously known or predicted to be inhibited by mebendazole, or previously implicated in ADPKD. This evidence concerns the gene WEE1 and autosomal dominant polycystic kidney disease.